Skip to main content
Equibles
ICUI logo

ICUI · Icu Medical Inc/De

Track ICUI — free

Use ICUI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$167.58 +1.29 (+0.78%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 19% of revenue

One customer — 19% of revenue (six months ended June 30, 2026)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 19% of revenue (three months ended June 30, 2026)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 19% of revenue (three months ended June 30, 2025)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”

One customer — 18% of revenue (six months ended June 30, 2025)

“For the three and six months ended June 30, 2026, our consolidated worldwide net sales to a single distributor were 19%, and 19%, respectively, and for the three and six months ended June 30, 2025, were 19% and 18%.”
View the 10-Q filed Aug 6, 2026
Market Cap
$4.19B
Shares
25.01M

ICUI metrics

91 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$167.58
Market cap
$4.19B

Price action

19 metrics
Price change (1W)
-4.3%
Price change (30D)
-9.2%
Price change (3M)
+22.7%
Price change (6M)
+27.0%
Price change (YTD)
+17.5%
Price change (1Y)
+33.4%
Trailing year
Price change (5Y)
-17.4%
52-week high
$187.26
52-week low
$114.13
Change from 52-week high
-10.5%
Change from 52-week low
+46.8%
Annualized volatility
36.2%
Beta
1.1
RSI (14D)
41.2
Price vs SMA 50
+0.2%
Price vs SMA 200
+15.1%
Avg volume (3M)
298,769
Relative volume
0.6
Average dollar volume
$48.21M

Company

3 metrics
Sector
Healthcare
Industry
Medical Instruments & Supplies
Shares outstanding
25.01M

Valuation

12 metrics
P / E (TTM)
140.8
Trailing earnings · reciprocal yield 0.7%
PEG ratio
—
EV / revenue
2.4×
reciprocal yield 42.2%
EV / EBITDA
18.7×
reciprocal yield 5.3%
EV / EBIT
71.1×
reciprocal yield 1.4%
P / sales
1.9×
reciprocal yield 51.5%
P / book
1.9
reciprocal yield 51.3%
FCF yield
3.6%
TTM · current market cap
Buyback yield
0.1%
P / FCF
27.4
reciprocal yield 3.6%
P / operating cash flow
17.7
reciprocal yield 5.6%
Earnings yield
0.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
826.9×
reciprocal yield 0.1%
EV / revenue historical average (3Y)
2.0×
reciprocal yield 50.2%
EV / revenue historical average (5Y)
2.3×
reciprocal yield 44.4%
EV / EBIT historical average (3Y)
274.2×
reciprocal yield 0.4%
EV / EBIT historical average (5Y)
294.5×
reciprocal yield 0.3%
EV / EBITDA historical average (3Y)
18.2×
reciprocal yield 5.5%
EV / EBITDA historical average (5Y)
21.3×
reciprocal yield 4.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.1%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
39.1%
Operating margin
3.3%
Trailing 12 months
Net margin
1.4%
Gross profit (TTM)
$845.14M
Operating profit (TTM)
$72.06M
Net income (TTM)
$30.09M
Trailing 12 months
Diluted EPS (TTM)
$1.19
FCF margin
7.1%
Effective tax rate
-4,105.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$63.77

Growth

11 metrics
Revenue growth YoY
+0.5%
Year over year
Net income growth YoY
-46.0%
Revenue (TTM)
$2.16B
Trailing 12 months
EPS growth YoY
-46.9%
Shares change YoY
+1.4%
Year over year · more shares
Revenue CAGR (3Y)
-0.7%
Revenue CAGR (5Y)
+11.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-62.5%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
-6.8%

Quality

14 metrics
Return on equity
1.4%
Return on assets
0.8%
Debt / equity
0.6
Current ratio
2.4
EBITDA (TTM)
$273.33M
Free cash flow (TTM)
$152.83M
Quick ratio
1.2
Interest coverage
0.9
Net debt / EBITDA
3.4
Return on invested capital
—
Trailing 12 months
Net cash
−$932.90M
Latest balance sheet
Cash & equivalents
$298.30M
Total assets
$3.97B
Total debt
$1.23B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$236.37M
Capital expenditures (TTM)
$83.54M
R&D (TTM)
$86.32M
SG&A (TTM)
$615.07M
Stock compensation (TTM)
$55.00M
R&D / revenue
4.0%
Stock compensation / revenue
2.5%

Ownership (13F)

3 metrics
13F filers
289
13F filer change QoQ
+12
Institutional ownership
104.5%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 3.6 days to cover
Days to cover
3.6d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$6.63M
Insider-sentiment score
18 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 883984 CUSIP 44930G107 13F (30d) 189 filings 188 filers Visit website Investor relations